Abstract Introduction CD52 (Campath-1 antigen), a glycoprotein of 12 amino acids anchored
to glycosylphosphatidylinositol, is widely expressed on the cell surface of immune cells …

The interest in regulatory B cells (Bregs) began in the 1970s with the evidence that B cells
could downregulate the immune system by the production of “inhibitory” antibodies …

Objective: To assess long-term survival, graft function, and health-related quality of life
(QOL) after visceral transplantation. Background: Despite continual improvement in early …

Antibodies confer humoral immunity but can also be harmful when they target an
autoantigen, alloantigen, allergen, or biotherapeutic. New strategies are needed for antigen …

Despite improvement in early outcome, rejection particularly chronic allograft enteropathy
continues to be a major barrier to long-term visceral engraftment. The potential role of donor …

Vaccines remain one of the most important pillars in preventative medicine, providing
protection against a wide array of diseases by inducing humoral and/or cellular immunity. Of …

The aim of the following review is to shed light on the putative role of regulatory B cells
(Bregs) in various human diseases and highlight their potential prognostic and therapeutic …

Current treatments for unwanted antibody responses largely rely on immunosuppressive
drugs compromising overall immunity. New approaches to achieve antigen-specific …

Unwanted antibody responses significantly impact human health, and current options for
treating deleterious antibody responses largely rely on broad immunosuppressants that can …

Transplantation is the preferred treatment for most end-stage solid organ diseases. Despite
potent immunosuppressive agents, chronic rejection remains a real problem in …